Background: The feasibility of concurrent chemotherapy and radiotherapy for advanced primary carcinoma of the cervix was evaluated and the results were compared to historical controls.
Introduction
Although the overall mortality of carcinoma of the uterine cervix has been markedly reduced by the widespread availability of effective cytologic screening programs, survival by stage has not changed significantly over the past 15 years [1, 2] . Forty to fifty percent of patients treated for invasive cervical cancer eventually relapse and the prognosis of these patients is extremely poor with only 6% of patients surviving more than 3 years [3] .
The results of surgery in the early stages of invasive cervical cancer have hardly changed [4] . Modern radiotherapy techniques have achieved better local control than in older series [1, 5] . However, depending on tumor stage and size, radiotherapy may fail in 10%-50%. This has stimulated the design of studies combining radiotherapy and chemotherapy. Combination with chemotherapy might improve local control and enhance radiation effects, simultaneously affecting subclinical metastases [6] .
The value of chemotherapy has been most extensively studied in patients with metastatic disease. Single agents will result in remissions in 10%-25% of patients, but the duration of most responses is limited and this will have only a modest effect upon survival [6] .
Although cisplatin is the most active drug in cervical cancer, its analog carboplatin will achieve 15%-25% response when used as a single agent and 26%-60% combined with other drugs [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
For the (neo-)adjuvant setting, there is no agreement on the optimal drug or drug combination, the timing or the sequence of chemotherapy and irradiation. The most marked effects are found when chemotherapy given simultaneously with radiotherapy. Cisplatin is a well-known radio-sensitizer [18] . Carboplatin shares the radio-sensitizing potential with cisplatin in experimental systems [19] . 5-Fluorouracil also has radiation enhancer capacities in vitro and clinically [20] .
Based on these data, a study was initiated combining simultaneous radio-and chemotherapy, its main aim being the improvement of local control. A combination of carboplatin and 5-FU was expected to induce less gastrointestinal and renal toxicity with moderate myelotoxicity than the reported side effects of cisplatin in this setting. The use of this combination has not been reported earlier for patients with cervical carcinoma. A group of patients which was treated previously in the same institution with the same radiotherapeutic schedule without chemotherapy served as a control group. In both groups, an additive hysterectomy was considered after completion of combined treatment.
Patients and methods
Patients with FIGO bulky stage IB and HA disease (>4 cm), and tumors stage IB, III and FVA were eligible for this single institution study. Entry criteria comprised a histopathologic proven diagnosis of primary carcinoma of the uterine cervix; age younger than 70 years with no past history of malignancy, no prior surgery, radiotherapy or chemotherapy. Patients with a WHO performance status 3 and 4 were excluded, as were patients with a leukocyte count <3.0 x 10 9 /l and/or platelet counts < 125 x 10 9 /l, serum creatinine >120 u.mol/1 and/or creatinine clearance <60 ml/min and patients with severe cardiac or infectious diseases. The staging of all patients was performed by a gynecologic oncologist together with a radiation oncologist under general anaesthesia.
Pretreatment assessment included complete blood counts and blood chemistry, creatinine clearance, chest X-ray, abdominal and pelvic CT-scan, intravenous pyelography and on indication cystoscopy. Assessment of rumor response was performed 6 weeks after completion of radiotherapy, clinically according to the WHO/UICC criteria and histologically by biopsy or hysterectomy. For the evaluation of toxicity, the WHO criteria were adopted. Blood counts were performed weekly, and serum creatinine and liver functions monthly during treatment.
Follow-up consisted of general and gynecologic examinations with cytology, blood counts and SCC-ag every 3 months during the first 2 years and every 6 months thereafter. Chest X-ray and CT abdomen were performed every year. The study was approved by the local Medical Ethical Committee and all patients gave informed consent before entry.
The characteristics and treatment results of the patients receiving combined treatment (group I) are compared with a control group, comprising all consecutive patients who were treated with the same radiotherapy schedule as the sole modality over the preceding period (group n). The criteria for performing surgery in these patients were the same as for the patients in group I.
Treatment

Radiotherapy
Radiation therapy was delivered by a 6 megavolt (MeV) photon linear accelerator. The 'box' technique was used comprising an anterior, posterior and two lateral fields. The superior limit of the antero-posterior fields was the upper border of the fourth lumbar vertebra, the lower limit was the lower margin of the obturator foramen (or, in stage I1I-A, the distal vagina). The lateral margin was 2 cm lateral from the transverse diameter of the pelvic brim. For the lateral fields, the ventral limit was the upper margin of the symphysis and the dorsal limit was the front of the os coccyx. Radiation was given by 1.8 Gy daily fractions, five days per week for a total dose of 45 Gy. All fields were treated daily. Two weeks after completing the external beam irradiation, a second examination under general anaesthesia was performed and if technically feasible, a 137 Cesium application of 17.5 Gy to point A, was repeated after one week for a total dose of 35 Gy. If brachytherapy was impossible or inappropriate in case of tumor extension into the parametria or lymph nodes, patients received an additional external boost of 35 Gy over 2 weeks for a total dose of 70.2 Gy.
Chemotherapy
Patients in group I received chemotherapy comprising 3 cycles of carboplatin and 5-FU. Carboplatin, 300 mg/m 2 , was dissolved in 250 mL 5% glucose and given over 30 min intravenously (i.v.) on day 1. 5-FU, 600 mg/m 2 , was dissolved in 2 1 normal saline and administered a continuously i.v. days 2-5. Cycles were repeated after 28 days for a total of 3 during the first, fifth and ninth week of treatment. Dose modifications only concerned carboplatin. If at the start of the second or third cycle the leukocyte count remained below 2.5 x lO'/l, the chemotherapy administration was postponed 1 week. If after 1 week the leukocyte counts had not recovered, the carboplatin dose was 25% reduced. Cycle 3 was given together with the external boost or in sequence to the second application of 137 Cesium brachytherapy.
Surgery
The feasibility of surgery was evaluated by a gynecologic examination under general anesthesia. If the gynecologist considered a radical resection possible and biopsies proved to be positive for tumor, a hysterectomy was performed about 6 weeks after completion of radiation. It comprised an extrafascial hysterectomy and removal of enlarged lymph nodes. In patients in whom a radical hysterectomy was not deemed feasible, or if multiple biopsies proved to be negative, a CT-scan was performed to evaluate the response.
Statistical analysis
Local tumor control, recurrence-free and overall survival probability were determined from the first day of treatment until death or last follow-up by a log-rank analysis according to Kaplan and Meier [27] . The characteristics and log-rank curves of group I and group II were compared with a Chi-square analysis.
Results
From April 1989 to December 1993, 74 consecutive patients with cervical carcinoma were treated with concurrent chemo-and radiotherapy. The characteristics of these patients (group I) and of 39 consecutive patients treated similarly from 1986-1989 but without chemotherapy served as historical controls (group n) are summarized in Table 1 . The characteristics did not differ for stage, grade and performance status between the two groups. The mean age of patients in group II is higher (58 versus 47 years), whereas the patients in group I had larger tumors, namely 59 (80%) versus 26 (66%) of patients with a tumor > 4 cm. Eight patients in group I had enlarged pelvic lymph nodes on CT-scan, which is a poor prognostic parameter. Enlarged paraaortic nodes were absent on the CT-scan.
The median follow-up for group I at evaluation is 28 months (range: 12-68+ months), and for group II 23 months (range 14-90+ months).
In group I all patients completed the full course of radiotherapy without interruption. Treatment was well tolerated. Leukocyte nadir grade I occurred in 18 (25%), grade H in 34 (46%), grade m in 20 (27%), and grade IV in two patients (3%). Thrombocytopenia grade I was observed in 58 (78%), grade II in 12 (16%), grade in in one and grade IV in two patients. In 22/ 222 (10%) chemotherapy cycles carboplatin was delayed 1 week for insufficient leucocyte recovery at the start of a cycle. Cycle 3 was deleted in one patient for grade IV thrombocytopenia. No bleeding or leukopenic fever were observed. Nausea and vomiting were mild (gTade 0: 35%; grade I: 37%; grade II: 28%), nor was there enhanced diarrhea due to chemotherapy. One patient died suddenly at home after completion of treatment but before tumor evaluation. She was known to have suffered a prior myocardial infarction. In a second patient there occurred one silent recurrent myo- cardial infarction as determined based on electrocardiogram changes before hysterectomy. One patient died after hysterectomy due to septicemia from small bowel lesions due to multiple adhesions in a cervical stump carcinoma-One patient had an accidental ureteral lesion during laparotomy which was treated with a temporary ureteral splint. One patient had a postoperative period of paralytic ileus which resolved with conservative therapy. Two patients developed deep venous thrombosis. No enhanced local toxicity from radiation was observed on the skin, rectum and bowel, or bladder compared with group n. The extent of skin fibrosis was not considered to be different from the group n. Most patients had mild diarrhea which was easily controlled with loperamide. In each groups two patients developed radiation enteritis. In group II one patient has developed a colon carcinoma 3 years later and another a uterine sarcoma 6 years after treatment In group I 73 patients are evaluable for tumor response. In 43 patients, a hysterectomy proved to be feasible. On pathological examination no tumor was found in 28 patients, 25 of whom still have no evidence of disease. At autopsy the patient who died postoperatively, proved to be free of tumor. Of the 15 patients with viable tumor cells in the hysterectomy specimen, 11 are still alive without evidence of disease (Table 2) . One patient also had viable tumor cells in enlarged para-aortic lymph nodes found at laparotomy, which were removed and treated with additional para-aortic radiation (45 Gy).
In 29 patients no hysterectomy but only cervical biopsies were performed 4-6 weeks after treatment In 23 no tumor was found of whom 14 are still disease free. Of the six with residual viable tumor cells only one is still free of disease progression. In one patient no histology was obtained as she developed lung metastases at the end of treatment. The predictive power of negative histology of the hysterectomy specimen is higher than that of biopsy, as 25/28 (89%) patients who had a histopathological complete remission remained disease free versus 14/23 (61%) patients who had negative biopsy findings (P < 0.05) ( Table 2) . Performing a salvage hysterectomy gives a therapeutic advantage as well, as 11/15 patients remained disease free despite positive pathology. In the 21 patients who had a relapse there were eight local, three combined local and distant and 10 in distant sites only. Thus, the local control in group I is 84% (Figure 4 ). Figure 1 . Overall survival in patients of group I and group II, comprising historical controls receiving only radiotherapy (P < 0.0032).
Overall Survival
Fourteen patients had unfavorable histology: adenosquamous in three, small-cell squamous in five, neuroendocrine type carcinoma in two and adenocarcinoma in four patients, patients. Five of them have relapsed, all at distant sites.
At 5 years the overall survival rate is 69% (Figure 1 ) This was for stage IB and UA: 75%; stage UB 75%; stage IUA+B: 47% (Figure 2) . The disease free survival at 5 years is 67% (Figure 3) . The local recurrence free survival at 5 years is 84% with no relapses occurring after 1 year (Figure 4) . Overall, 51 of 72 patients (71%) still are without evidence of disease and 21 patients (29%) have had disease progression. All local relapses occurred within 1 year after treatment, but distant metastases were seen up to 3 years thereafter.
In the historical control group, group n, 19 out of 39 underwent hysterectomy (ns versus group I). In nine patients residual viable tumor cells were present and of these patients only two are still alive without evidence of disease. In four there was a local relapse, in one a distant relapse and in one a combination of both. Compared to group I there is a reduced overall survival at 5 years (38% versus 69%), a lower percentage of local tumor control at 5 years (43% versus 84%), and a reduced progression free survival (43% versus 67% in group II (Figures 1, 3, 4) . In contrast to group I, in group II local relapses occurred also after more than one year. Comparison of the log-rank curves for group I and II by Chi-square analysis yields a better overall survival (P< 0.003), local control (P< 0.0001) and progression-free survival (P < 0.005).
Discussion
Chemotherapy can be used in several ways as an adjunct to local treatment of cervical cancer, e.g., as an adjuvant treatment, neo-adjuvant or concurrently with radiotherapy. When chemotherapy is used as an adjuvant after surgery, the results are not better than those achieved by local therapy as the only modality [22, 23] . Based on three randomized studies, the use of neoadjuvant chemotherapy was discouraged because it resulted in an inferior local control and possibly even worse overall survival. This is probably due to the delayed start of the local treatment and reduced radiation dose-intensity [24] .
Another approach is the simultaneous use of radioand chemotherapy, in which the systemic treatment is mainly applied as a radiation enhancer. Clinical studies have suggested a local benefit of the combination cisplatin with radiotherapy in other rumors, for example in advanced head and neck cancer and non-small cell lung cancer [25, 26] . In cervical carcinoma a combination of radiation with 5-FU has shown interesting results [27] . Combinations of radiotherapy with cisplatin and 5-FU for cervical cancer resulted in 60%-100% local control and 50%-90% disease free progression at 12-29 months follow-up [28] [29] [30] [31] [32] [33] [34] . Some authors have warned against for the limited tolerance of cisplatin plus 5-FU combined with full dose radiotherapy. Resbeut et al. observed local control in 80% after radiotherapy with cisplatin and 5-FU, but had to reduce the dose of both cisplatin and 5-FU and apply hyperfractionation of radiotherapy because of gastrointestinal toxicity [34] . Radiation delay occurred in 78% and in 54% of patients in a second study [35] . There is one phase HI study that suggests an improved response rate by cisplatin concurrently with radiotherapy [36] . Full reports on other ongoing randomized studies with combined radio-chemotherapy are not yet available.
In the present study the effect of radiotherapy with carboplatin and 5-FU plus salvage hysterectomy is compared with the same treatment without chemotherapy in a prior group used as historical controls. Radiotherapy could be administered uninterrupted and could be given in full dose. Local toxicity was not enhanced by combined treatment. Systemic toxicity was manageable as 90% of all chemotherapy cycles could be given without delay and there was no severe myelotoxicity. The late toxicity in this study appears to be mild, as the same frequency of radiation enteritis occurred in each treatment group. This schedule is markedly better tolerated than cisplatin as a single agent [37] or some cisplatin-based combinations [32] [33] [34] [35] .
The addition of carboplatin plus 5-FU resulted in a better overall survival, disease free survival and local control. After 1 year no local relapse have occurred. The local control by combined treatment was especially remarkable in view of the advanced tumor stage in most patients. Pearcey et al., in their relatively large series of 60 patients, combined concurrent cisplatin and radiation therapy and observed no further local relapses after 26 months [37] . They found a pelvic control rate of 78%. Adjuvant hysterectomy as a salvage treatment can play a role in selected cases with positive biopsy, as 77% patients with residual vital tumor in the resected specimen have remained disease free. Arai et al. have reported that positive biopsies 1-2 months after treatment invariably predict recurrence and are a strong indication for salvage surgery [38] .
The main problem remains the fact that distant metastases will still occur in 16% of our patients, indicating that the present regimen is still not sufficiently effective to eradicate disseminated tumor cells, especially in the group with unfavorable histology, the small cell and neuro-endocrine variants. In this category other, more aggressive systemic treatment might be indicated.
In conclusion, combined chemo-radiotherapy with carboplatin plus 5-FU appears to be an effective mode of treatment with remarkably limited toxicity in patients with an unfavorable prognosis cervical carcinoma.
